A multicenter, phase 1/2, basket study published in Nature Medicine included 45 patients with RET gene fusions (including 10 patients with colorectal cancer) and found significant anti-tumor activity of Selpercatinib in patients with RET fusion-positive advanced colorectal cancer. The gene discussed is RET; the disease is colorectal cancer.